Citigroup Inc Caribou Biosciences, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Citigroup Inc holds 71,375 shares of CRBU stock, worth $119,910. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,375

Previous 52,591 35.72%

Holding current value

$119,910

Previous $86,000 61.63%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.56 - $2.73 $29,303 - $51,280	18,784 Added 35.72%	71,375 $139,000
Q2 2024 Aug 12, 2024	SELL	$1.62 - $5.05 $675,424 - $2.11 Million	-416,929 Reduced 88.8%	52,591 $86,000
Q1 2024 May 10, 2024	BUY	$4.82 - $8.26 $1.48 Million - $2.54 Million	307,801 Added 190.33%	469,520 $2.41 Million
Q4 2023 Feb 09, 2024	SELL	$3.58 - $6.25 $212,820 - $371,543	-59,447 Reduced 26.88%	161,719 $926,000
Q3 2023 Nov 09, 2023	BUY	$4.08 - $8.14 $794,849 - $1.59 Million	194,816 Added 739.34%	221,166 $1.06 Million
Q2 2023 Aug 10, 2023	SELL	$4.04 - $5.47 $684,153 - $926,317	-169,345 Reduced 86.54%	26,350 $111,000
Q1 2023 May 11, 2023	BUY	$4.3 - $7.78 $398,124 - $720,326	92,587 Added 89.8%	195,695 $1.04 Million
Q4 2022 Feb 09, 2023	SELL	$5.57 - $11.01 $142,124 - $280,931	-25,516 Reduced 19.84%	103,108 $647,000
Q3 2022 Nov 10, 2022	BUY	$5.34 - $12.79 $611,958 - $1.47 Million	114,599 Added 817.11%	128,624 $1.36 Million
Q2 2022 Aug 10, 2022	SELL	$5.1 - $9.74 $43,166 - $82,439	-8,464 Reduced 37.64%	14,025 $76,000
Q1 2022 May 12, 2022	SELL	$8.42 - $15.32 $67,418 - $122,667	-8,007 Reduced 26.26%	22,489 $206,000
Q4 2021 Feb 10, 2022	BUY	$14.59 - $23.26 $412,473 - $657,583	28,271 Added 1270.61%	30,496 $460,000
Q3 2021 Nov 10, 2021	BUY	$15.75 - $30.29 $35,043 - $67,395	2,225 New	2,225 $53,000

Others Institutions Holding CRBU

# of Institutions

135

Shares Held

52.6M

Call Options Held

148K

Put Options Held

70.7K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $102M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account